Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bayer AG’s Unit Submits VEGF Trap-Eye (Aflibercept) For Treatment Of Macular Edema Following Central Retinal Vein Occlusion in Japan
Bayer AG’s Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) to the Ministry of Health, Labour and Welfare (MHLW) in Japan. The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies.
Latest Developments for Bayer AG
- Regeneron Pharmaceuticals Inc And Bayer AG's Bayer HealthCare Reports Positive Phase 3 Results For EYLEA (aflibercept) Injection In Myopic Choroidal Neovascularization (mCNV)
- Bayer AG's Subsidiary Acquires Majority Interest In Conceptus, Inc For USD1.1 Billion
- France Will Back Down Over Bayer AG's Acne Pill-Reuters
- Antitrust Clearance Obtained For Bayer AG's Bayer HealthCare LLC Acquisition Of Conceptus Inc
Latest Key Developments in Pharmaceuticals
- Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg
- Valeant Pharmaceuticals International Inc's VPII Escrow Corp Announces Launch Of Private Offering Of Senior Notes
- Hubei Guangji Pharmaceutical Co Ltd to Acquires 35% Stake in Subsidiary
- Valeant Pharmaceuticals International Inc Prices Public Offering Of Common Shares
- Share this
- Link this
- Digg this
Follow Reuters